Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
7(87.5%)
Phase 2
1(12.5%)
8Total
Phase 1(7)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07314294Phase 2Recruiting

Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

Role: lead

NCT07432022Phase 1Not Yet Recruiting

A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Role: lead

NCT04735575Phase 1Terminated

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Role: lead

NCT05176665Phase 1Recruiting

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Role: lead

NCT04618393Phase 1Terminated

A Study of EMB-02 in Participants With Advanced Solid Tumors

Role: lead

NCT05263180Phase 1Unknown

A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

Role: lead

NCT05498389Phase 1Unknown

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Role: lead

NCT03797391Phase 1Unknown

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Role: lead

All 8 trials loaded